SINCE SUCCINYLCHOLINE (Sch) is the most commonly used muscle relaxant in anaesthetic practice, considerable research has been conducted on its mode of action and metabolism. It is known that Sch is hydrolyzed by plasma cholinesterase (PChE). 1 Therefore, in the presence of reduced PChE activity, the intensity and the duration of the neuromuscular block is prolongedY After the discovery of an inherited, atypical PChE variant by Kalow et al., 3 the cognizance of conditions which may influence PChE activity, such as sex, age, and various disease states, became indispensable for the anaesthesiologist in the assessment of safe doses of Sch. 2,4,5
The inhibitors used were commercially prepared and purified dibucaine hydrochloride (Nupercaine hydroehloride), neostigmine bromide (Prostigmine bromide), and succinyldieholine chloride (Anectine, Suxamethonium, Quelicin, Sueostrin). The inhibitory effect was observed with the inhibitor concentrations presented in Tables I and II . Kinetic studies were also carried out with various BeCh and inhibitor concentrations to determine whether the inhibition was competitive or non-competitive with the three substrates. RESULTS Because of the sex difference in PChE activity reported by Shanor et al., 4 the results are grouped and analyzed according to sex, as shown in Tables I and II . It is evident that there was no significant difference at the p < 0.05 level~ between newborns and infants of identical sex with respect to the hydrolysis rates of either BeCh or Proc.
The comparison of the mean hydrolysis rates of BeCh and Proc by the PChE's of infants and newborns with the corresponding means of normal male and female adults indicated that the mean PChE activity of infants and newborns was found to be about 50 per cent of that of adults. The per cent inhibition of BeCh hydrolysis by dibueaine and Sch of neonatal and infant PChE was identical with that of adults. In contrast to adults, the PChE of infants and of newborns was relatively resistant to neostigmine inhibition.
Double reciprocal plots of the various concentrations of neostigmine, dibucaine, and Sch versus BeCh hydrolysis rates (Figures 1, 2, and 3) showed a competitive inhibition of the BeCh hydrolysis with all three inhibitors tested. These findings agree with the results of previous investigations. 2,a,9
DISCUSSION
On the basis of the findings, it may be concluded that the PChE of healthy, full-terna newborns and infants from birth to six months hydrolyze BeCh and Proe at half the rate of that of healthy, unmedicated adults. This observation tends to support the earlier findings of Bleisch and Schwaehman 1~ that newborns have a markedly lower PChE activity than adults. The infants studied by these authors, however, had severe organic diseases and therefore no valid conclusion could be drawn on the PChE activity of healthy, normal infants. Our findings further corroborate the results of MeCance et al. 11 who found 40 per cent reduction in PChE level in normal newborns as compared to normal adults. Low PChE activity of newborns was also observed by Abderhalden TM and Lehman. 13 The inhibitory effect of dibueaine and suecinyleholine on the neonatal and infant PChE corresponds to the former results in adults, 2,3 in contrast to the marked resistance of neonatal and infant PChE to neostigmine inhibition observed in this study.
With respect to the nature of the inhibition, our results confirm those of previous investigators indicating that all three inhibitors, Sch, neostigmine, and tStudent t-test dibucaine caused competitive inhibition, since increasing concentrations of BeCh reduced the inhibitory effect. The competitive nature of the inhibition of human PChE by neostigmine, however, has recently been questioned by Foldes e t al. 14 who showed that the degree and type of inhibition depends not only on the concentration of neostigmine but also on the duration of preincubation with the enzyme. This point should be further clarified.
Although Telford and Keats 15 reported that an inverse relationship existed between age and the Sch dose required to maintain apnea from early infancy to 10 years of age, Lim e t al. 16 found that infants less than 1 year old are more sensitive to this drug. The latter authors found that a dose of 0.33 mg/Kg that caused no apnea in children over a year old, did produce apnea in all infants under one year. On the other hand, even though recovery time from the neuromuscular block was shorter in infants than in children over one year, the muscle relaxant effect of identical intravenous doses was greater in infants than in children. This shortened recovery time may reflect a more rapid dilution of Sch in the blood of infants, since their blood volume relative to body weight is larger than that of adults or it may be due to the different sensitivity of the neuromuscular end-plates of infants to muscle relaxants as reported by Churehill-~avidson. a7 The contradictory findings on the sensitivity of newborns and infants to Seh may further be reconciled by the fact that the patients studied by Telford and Keats 15 had had pathologic changes which might have offset the fluid and electrolyte balance and the normal metabolic and enzyme funetions.
Sinee there is a fixed ratio between the hydrolysis rates of BeCh and Sch in patients with normal homozygous PChE, 2 and since the measurement of Sch hydrolysis rates involves major inaccuracies and technical difficulties, the hydrolysis rate of PChE-Speeifie substrate, BeCh was accepted as an indirect measure of Sch hydrolysis rate by PChE. Consequently, it was assumed that newborns and infants hydrolyze Seh at about half the adult rate.
Although no definite conclusions can be drawn from the results of this study as to the muscle relaxant requirements or the in vivo metabolism of Sch in newborns and infants, it is definitely established that PChE activity per ml plasma of neonates and infants is approximately half that of adults. Therefore, it is likely that after intravenous infusion of identical mg/kg/min doses of Sch, the blood levels of Sch will be higher in newborns and infants than in adults. This assumption is corroborated by the findings of Kvisselgaard and Moya is that the actual blood level of Sch measured by biologic titration in adult patients was primarily dependent on two factors: (1) The rate of infusion of Sch, and (2) PChE activity. Since the development of bradyeardia and eardiae arrest in infants and newborns will ultimately depend on the blood level of Seh attained in the heart, we recommend that the mg/kg/min infusion rate of Seh should be redueed twofold as compared to that required in adults for complete muscle relaxation in order to avoid cardiac arrhythmias. As an alternative, the intramuscular route of administration may be chosen. The findings of Lim et al. is that the intravenous apneie dose of Seh in infants, younger than one year, was approximately 0.33 mg/Kg as compared to 0.66 mg/Kg in children over one year may serve as a baseline for the calculation of the safe muscle relaxant doses of Seh for this age group.
Studies on the dose-response eurves of Sch with the aid of electromyography, PChE, and actual Sch blood level determinations are currently in progress with a view toward the objective assessment of Seh sensitivity in newborns and infants.
SUM_~IAI1Y
In a group of 42 healthy newborns and infants to the age of 6 months, the hydrolysis rates of benzoyleholine and procaine by the plasma cholinesterase were found to be about half the rates observed in 322 healthy adults. In contrast to adults, a marked resistance of infant plasma eholinesterase to neostigmine inhibition was found. The low plasma eholinesterase activity of newborns and infants to 6 months of age should be taken into account in the caleulation of safe doses of succinylcholine in order to prevent cardiac arrest and/or prolonged apnea.
